A Prospective, Single Arm, Open Label, Single Center study to evaluate the Immunogenicity and Safety of Two Doses of Live Attenuated Varicella Vaccine (VR 795 Oka Strain) in Healthy Indian Adults and Adolescents

Start Date10 Oct 2017

Sponsor / Collaborator-

EUCTR2013-003535-30-EE / Not yet recruitingPhase 3

A Phase III, double blind, randomized, comparative study of the safety and immunogenicity of GSK Biologicals’ Varilrix HSA-free varicella vaccine and Varilrix™ given as a 2 dose course in the second year of life - OKAH-193

Start Date17 Nov 2015

Sponsor / Collaborator

GlaxoSmithKline LLC

NCT02570126 / CompletedPhase 3

Safety and Immunogenicity Study of 2 Formulations of GSK Biologicals' Varicella Vaccines Given as a 2-dose Course in the Second Year of Life.

The purpose of this study is to evaluate the safety and immunogenicity of 2 formulations of GSK Biologicals' varicella vaccines given as a 2-dose course in the second year of life.

Start Date13 Nov 2015

Sponsor / Collaborator

GSK Plc

100 Clinical Results associated with Varicella attenuated live vaccine(Osaka University)

100 Translational Medicine associated with Varicella attenuated live vaccine(Osaka University)

100 Patents (Medical) associated with Varicella attenuated live vaccine(Osaka University)

154

Literatures (Medical) associated with Varicella attenuated live vaccine(Osaka University)

01 Jan 2024·Vaccine

Parental perceptions of chickenpox and the varicella vaccine: A qualitative systematic review

Review

Author: Rowland, Emma ; Jordan, Zoe

BACKGROUND:

In countries where varicella vaccination is not on the routine childhood immunisation schedule, such as those in the United Kingdom (UK), chickenpox is an almost universal disease of childhood. Chickenpox can cause serious complications, particularly in infants, pregnant women, and the immunocompromised. In November 2023 the varicella vaccine was recommended for inclusion in the UK routine childhood immunisation schedule. Successful rollout of the vaccine may be hindered by parental concerns about vaccine safety and efficacy, and perceptions of chickenpox as a mild illness.

OBJECTIVE:

To examine parental perceptions of chickenpox and varicella vaccination, which may be crucial to effective vaccination campaigns.

DESIGN:

Qualitative systematic review and thematic analysis.

METHODS:

Six electronic databases were systematically searched for studies published between 2016 and 2023: CINAHL, EMBASE, MEDLINE, PsycInfo, PubMed, and Web of Science. The included studies were appraised against the Critical Appraisal Skills Program checklist for qualitative studies. Thematic analysis was used to analyse qualitative data, through the development of themes.

RESULTS:

22 articles were included in this review, and five themes identified: perceptions that chickenpox is a mild illness, that parents have concerns about varicella vaccine efficacy and safety, a notion of natural immunity as superior, social determinants of health influence vaccine decision making, and vaccination is overwhelming perceived as a parental decision.

CONCLUSIONS:

Whilst some parents displayed an acceptance and willingness to vaccinate against chickenpox, many expressed concerns, and perceived chickenpox as a routine unworrying childhood illness. Analysis demonstrated a knowledge gap in understanding UK parental opinions regarding chickenpox and varicella vaccination, highlighting the need for research in this area, particularly given ongoing reconsideration for inclusion in the UK vaccination schedule.

REGISTRATION:

The review was registered on PROSPERO, registration ID CRD42021236120.

17 Nov 2023·Postgraduate medicine

Vaccination coverage of children with rheumatic diseases compared with healthy controls: a retrospective case-control study

Article

Author: Çakmak, Figen ; Önel, Mustafa ; Aktay Ayaz, Nuray ; Demirkan, Fatma Gül ; Eker Ömeroğlu, Rukiye ; Keskindemirci, Gonca ; Gökçay, Emine Gülbin ; Akgün, Özlem ; Akay, Nergis ; Kavrul Kayaalp, Gülşah ; Erdemir, Merve

OBJECTIVE:

To reveal the vaccination status of patients with pediatric rheumatic disease (PedRD) and to compare this with healthy controls.

METHODS:

The electronic health records of the Ministry of Health regarding the vaccination status of children with PedRD followed in a tertiary hospital were analyzed cross-sectionally and compared with their healthy controls. The missing vaccines were reported according to individual, age-appropriate schedule and causes of skipped vaccines in both groups were investigated with an online survey.

RESULTS:

The vaccination rate of patients in the last examination was 71.4% (90/126) and 95.7% (110/115) in healthy controls (p < 0.001). Measles-mumps-rubella vaccine, diphtheria, the administration rates of the second dose of tetanus-acellular pertussis-inactivated polio and Haemophilus influenzae type B, chickenpox, and hepatitis A vaccines were significantly lower in patients than in controls (p values 0.004, 0.02, 0.01, 0.013, respectively). The pre-diagnosis incomplete vaccination proportion was significantly higher in the patient group (16.6%) than in healthy controls (4.3%) (p = 0.002). In the patient group, the proportion of incomplete live-attenuated vaccines after diagnosis (25%) was more than pre-diagnosis (61.1%) (p = 0.04), while the proportion of incomplete non-live vaccines before and after diagnosis was similar (47.2% and 50%, respectively) (p = 0.73). The major reasons for missed vaccines were physicians' recommendations (15.6%), the presence of PedRD diagnosis (12.5%), and the drugs used (12.5%).

CONCLUSION:

Vaccination coverage of PedRD patients has been shown to lag behind the routine vaccination schedule (71.4%). In addition to new recommendations, electronic health system records for vaccination may be appropriate for the follow-up of these patients, and the addition of reminder alerts may be useful to reduce the rate of missed vaccinations.

16 May 2023·Journal of medical Internet research

Using Baidu Index Data to Improve Chickenpox Surveillance in Yunnan, China: Infodemiology Study.

Article

Author: Han, Chenyu ; Zhang, Lizhi ; Zhang, Xinyao ; Tiejun, Shui ; He, Jun ; Zhao, Meifang ; Zhen, Qing ; Wang, Hao ; An, Shuqi ; Wang, Meiqi ; Jin, Bolin ; Wang, Zhaohan

BACKGROUND:

Chickenpox is an old but easily neglected infectious disease. Although chickenpox is preventable by vaccines, vaccine breakthroughs often occur, and the chickenpox epidemic is on the rise. Chickenpox is not included in the list of regulated communicable diseases that must be reported and controlled by public and health departments; therefore, it is crucial to rapidly identify and report varicella outbreaks during the early stages. The Baidu index (BDI) can supplement the traditional surveillance system for infectious diseases, such as brucellosis and dengue, in China. The number of reported chickenpox cases and internet search data also showed a similar trend. BDI can be a useful tool to display the outbreak of infectious diseases.

OBJECTIVE:

This study aimed to develop an efficient disease surveillance method that uses BDI to assist in traditional surveillance.

METHODS:

Chickenpox incidence data (weekly from January 2017 to June 2021) reported by the Yunnan Province Center for Disease Control and Prevention were obtained to evaluate the relationship between the incidence of chickenpox and BDI. We applied a support vector machine regression (SVR) model and a multiple regression prediction model with BDI to predict the incidence of chickenpox. In addition, we used the SVR model to predict the number of chickenpox cases from June 2021 to the first week of April 2022.

RESULTS:

The analysis showed that there was a close correlation between the weekly number of newly diagnosed cases and the BDI. In the search terms we collected, the highest Spearman correlation coefficient was 0.747. Most BDI search terms, such as "chickenpox," "chickenpox treatment," "treatment of chickenpox," "chickenpox symptoms," and "chickenpox virus," trend consistently. Some BDI search terms, such as "chickenpox pictures," "symptoms of chickenpox," "chickenpox vaccine," and "is chickenpox vaccine necessary," appeared earlier than the trend of "chickenpox virus." The 2 models were compared, the SVR model performed better in all the applied measurements: fitting effect, R²=0.9108, root mean square error (RMSE)=96.2995, and mean absolute error (MAE)=73.3988; and prediction effect, R²=0.548, RMSE=189.1807, and MAE=147.5412. In addition, we applied the SVR model to predict the number of reported cases weekly in Yunnan from June 2021 to April 2022 using the same period of the BDI. The results showed that the fluctuation of the time series from July 2021 to April 2022 was similar to that of the last year and a half with no change in the level of prevention and control.

CONCLUSIONS:

These findings indicated that the BDI in Yunnan Province can predict the incidence of chickenpox in the same period. Thus, the BDI is a useful tool for monitoring the chickenpox epidemic and for complementing traditional monitoring systems.

News (Medical) associated with Varicella attenuated live vaccine(Osaka University)

08 Apr 2024

·www.globenewswire.com

Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer

Chi Li, PhD, MBA, RAC adds over 20 years of global regulatory experience and success to the Curevo Vaccine executive teamSEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus vaccines with improved tolerability and accessibility, today announced Dr. Chi Li is joining as the company’s Chief Regulatory Officer responsible for the global regulatory strategy for amezosvatein. “We are thrilled to have Dr. Li join the Curevo team and build upon the regulatory progress made thus far,” stated George Simeon, Curevo’s Chief Executive Officer.” Dr. Li will play a key role in finalizing our global regulatory strategy and harmonizing our approach to key entry markets in Europe, the USA, China, Japan, and other important markets for our shingles and varicella vaccine.” Dr. Li’s impressive 20+ year career in regulatory affairs features multiple regulatory successes globally. He’s played an instrumental role in the development, submission, and approval of drugs and biologics across several disease areas including in the infectious disease space. “I’m genuinely impressed at what the Curevo team has accomplished to date and am excited to join such a dynamic group,” said Dr. Li. “There is a clear unmet need in both shingles and varicella immunization, and I look forward to working with the Curevo team and our global partners to bring this active vaccine with significantly improved tolerability to market quickly.” Dr. Li was most recently the Chief Regulatory Officer at Editas Medicine and held the same role prior to Editas at Celularity. Previously, Dr. Li served as Vice President, Regulatory Affairs at both Allergan and Bayer. He also held regulatory affairs roles with increasing responsibilities at Bristol-Myers Squibb, Pfizer, and Johnson & Johnson. Dr. Li earned a PhD in organic chemistry from Purdue University and an MBA from Rutgers University. He holds a Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professionals Society. About Curevo VaccineCurevo is a privately held, clinical-stage biotechnology company based near Seattle and is dedicated to reducing the burden of infectious disease by developing vaccines with improved tolerability and accessibility. Curevo’s lead product is amezosvatein, a non-mRNA sub-unit vaccine to prevent shingles, a serious medical condition involving a painful, blistering skin rash where 10-18% of people also develop serious, long-lasting nerve pain. The current $4+ billion shingles vaccine market is characterized by accessibility issues and vaccine hesitancy/dose avoidance related to vaccine tolerability. Curevo is also developing a non-live, non-mRNA subunit chickenpox vaccine intended to reduce or eliminate barriers to immunizing immunocompromised children. For more information visit https://curevovaccine.com/.

VaccineExecutive ChangemRNA

08 Feb 2024

·www.prnewswire.com

Global Market Pipeline for Vaccine Technologies 2024-2028

DUBLIN, Feb. 8, 2024 /PRNewswire/ -- The "Global Markets for Vaccine Technologies" report has been added to ResearchAndMarkets.com's offering. Advancements will occur in regard to the development of novel vaccines towards emerging infectious diseases, cancers and allergies. Continuous improvements in vaccine design, delivery technologies and manufacturing will also boost market growth. The global vaccine technologies market is segmented in this report by technology, disease, age, and region. This report explains critical trends in the vaccine industry. It discusses the market determinants, which act as motivating or restraining factors and provides insights to stakeholders and potential entrants. This report includes only human vaccines; animal vaccines have not been considered in this report. This study looks at research and development (R&D) spending, increasing competition and new technologies, which are giving direction to the market. These advancements, new product launches and changing lifestyles are influencing future market growth. Company mergers, acquisition strategies and collaborations are also covered in this report. Additionally, this study discusses the strengths and weaknesses of each strategy type, considering new technologies, growing competition and changing customer needs. The market has been analyzed based on the application of current vaccines. Categories considered in this report include pneumococcal vaccines; diphtheria, tetanus vaccines; HPV vaccines; MMR vaccines; and other vaccines including rotavirus vaccines, influenza vaccines, hepatitis B vaccines, chickenpox vaccines, polio vaccines, BCG, and yellow fever vaccines. This study details market growth among vaccine manufacturers and end users. Genomic research centers, academic institutions, government and private laboratories, various hospital settings, and pharmaceutical, diagnostic and biotechnology companies and physicians will find this study to be of interest. This report provides useful information to all market players, potential entrants, government agencies and other interested parties. As the report covers geographic regions in detail, companies interested in expanding geographic reach will also find this study useful. The Report Includes 34 data tables and 63 additional tables An up-to-date overview of the global markets for vaccine technologies Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028 Estimate of the market size and revenue forecast for the global market, and a corresponding market share analysis based on technology, disease indication, age group and region Facts and figures pertaining to the market drivers, opportunities and challenges, emerging technologies, global R&D spending, and the regulatory landscape Assessment of present and future strategies in the innovation-driven vaccine technologies market, and a look at the vaccines for humans and their immunization schedule Discussion of the importance of ESG in the market for vaccine technologies, including consumer attitudes, the impact of ESG factors on company performance, and ESG practices of leading companies Review of patents and patent applications Overview of the major vendors, along with an analysis of the industry structure, including company market shares, recent M&A activity, and venture funding Analysis of the competitive landscape based on recent developments and segmental revenues Profiles of the leading companies Key Topics Covered: Chapter 1 Introduction Chapter 2 Summary and Highlights Chapter 3 Market and Technology Background Immune System and Vaccines Components of the Immune System Cells of the Immune System Immune Response Major Histocompatibility Complex (MHC) Immunization and Vaccines Disorders of the Immune System Impact of Lifestyle on the Immune System How Vaccines Work Principles of Immunization Types of Immunity Advantages of Vaccination History of Vaccines Vaccines and Immunization, Overview Types of Vaccines Attenuated (Live) Vaccines Inactivated (Killed) Vaccines Toxoid Vaccines Subunit Vaccines Conjugate Vaccines Recombinant Vector Vaccines DNA Vaccines RNA Vaccines Immunization Advantages of Immunization Adjuvants and Excipients Pathogen Components Particulate Adjuvants Infectious Diseases Preventable by Vaccine Human Diseases Viral Diseases Bacterial Diseases Regulatory Aspects World Health Organization (WHO) Prequalified Vaccines New Product Approvals Recalls Significant Regulatory Developments in Vaccines Chapter 4 Market Dynamics Market Drivers Growing Awareness of Immunization Growing Investments and R&D New Vaccines Prevalence of Infectious Diseases Market Restraints Vaccine Development and Pricing Market Opportunities Increased Demand from Emerging Markets Therapeutic Vaccines Chapter 5 Global Market for COVID-19 Vaccines COVID-19 Vaccine Technologies Advent of mRNA Technology Impact of COVID-19 on Routine Infant Vaccination COVID-19 Disruptions Stagnating Global Coverage Rate Progress and Challenges by Country and Region Chapter 6 Market Breakdown by Technology Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines Live-Attenuated Vaccines Inactivated Vaccines Toxoid Vaccines Other/Combination Vaccines Chapter 7 Market Breakdown by Disease Pneumococcal Diphtheria and Tetanus HPV MMR Chapter 8 Market Breakdown by Age Group Pediatrics Adolescents and Adults Chapter 9 Market Breakdown by Region Chapter 10 Emerging Technologies and Developments Developments mRNA Vaccines Viral Vector Vaccines Nanoparticle Vaccines DNA Vaccines Virus-Like Particle (VLP) Vaccines Self-Amplifying RNA Vaccines Innovative Adjuvants AI and Computational Biology Personalized Vaccines Plant-Based Vaccines Chapter 11 Competitive Landscape Chapter 12 Company Profiles Abbott Astrazeneca Bavarian Nordic Bharat Biotech International Emergent Biosolutions GSK Johnson & Johnson Services Merck Mitsubishi Tanabe Pharma Corp. Panacea Biotec Pfizer Inc. Sanofi For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

VaccinemRNA

21 Dec 2023

·www.globenewswire.com

Curevo Vaccine to present at the 42nd Annual J.P. Morgan Healthcare Conference

SEATTLE, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced it has been selected to present in the Private Company Track at the 42nd Annual J.P. Morgan Healthcare Conference. Curevo’s CEO, George Simeon, will discuss data from Curevo’s 876-patient head to-head trial of CRV-101, a non-mRNA adjuvanted subunit vaccine for shingles, versus Shingrix®. The presentation will occur on Wednesday, January 10th at 4:00pm Pacific Standard USA Time (PST) in the Golden Gate room (32nd floor). About Curevo VaccineCurevo is a privately held, clinical-stage biotechnology company based in Seattle and dedicated to reducing the burden of infectious disease by developing safe and highly effective vaccines. Its lead product is CRV-101, a non-mRNA sub-unit vaccine to prevent shingles, a serious medical condition involving a blistering skin rash where 10-18% of people also develop serious, long-lasting nerve pain. The currently $4 billion shingles vaccine market is characterized by accessibility issues and vaccine hesitancy/dose avoidance related to the burden of vaccine-related side effects. Curevo is also developing a non-live, non-mRNA subunit chickenpox vaccine. For more information visit https://curevovaccine.com/. Shingrix® is a registered trademark of GlaxoSmithKline, PLC.

VaccinemRNA

100 Deals associated with Varicella attenuated live vaccine(Osaka University)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07BK01	DB10318

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Chickenpox	GB	GSK Plc	25 Jun 2002

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Measles	Phase 3	AT	GSK Plc	01 Jul 2004
Measles	Phase 3	DE	GSK Plc	01 Jul 2004
Mumps	Phase 3	AT	GSK Plc	01 Jul 2004
Mumps	Phase 3	DE	GSK Plc	01 Jul 2004
Rubella	Phase 3	AT	GSK Plc	01 Jul 2004
Rubella	Phase 3	DE	GSK Plc	01 Jul 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00624819 (CTgov)	Phase 3	Pneumonia, Pneumococcal	524	GSK1024805A+Varilrix+Infanrix hexa+Havrix (Synflorix + Infanrix + Havrix and/or Varilrix Group)	oyfdphqluq(hozpnkcqbe) = jpwwbfswco jalanckjrw (sxivimlnqg, gabjchdgjk - cadwjofeba) View more	-	18 Mar 2020
				Varilrix+Infanrix hexa+Havrix+Prevenar (Prevenar + Infanrix + Havrix and/or Varilrix Group)	oyfdphqluq(hozpnkcqbe) = hshenerals jalanckjrw (sxivimlnqg, lvemucstiy - qsnbtzdjiz) View more
NCT00226499 (CTgov)	Phase 3	Chickenpox \| Measles \| Rubella ... View more	5,803	Priorix-tetra™ (MMRV Group)	aanaehvssd(zrwclpvyuy) = qckmyamffo fuzdrjlfis (gzlgdgqvxz, bemrapkcjc - nvkyvbqmro) View more	-	23 Sep 2019
				Varilrix™+Priorix™ (OKAH Group)	aanaehvssd(zrwclpvyuy) = secpxgcgqx fuzdrjlfis (gzlgdgqvxz, wirnmdtsmp - ipgregkfyw) View more
NCT02570126 (CTgov)	Phase 3	Chickenpox	1,236	Varilrix HSA-free (VAR_HSA_F Group)	fdhygjslyk(evuafhbkkx) = cteplctzew tszbczzdtd (xtsnwnbyvy, lcxyajwctc - mhvajfxhvt) View more	-	11 Oct 2017
				Varilrix™ (VAR Group)	fdhygjslyk(evuafhbkkx) = sjlwhqijsi tszbczzdtd (xtsnwnbyvy, yjsjqdkgnn - yostncnrsu) View more
NCT00792623 (CTgov)	Phase 2	Chickenpox	45	VarilrixTM	sfjgjkryxt(lxxozozhqe) = xgglwibolf cfnqqvazyk (tcqonduujm, xziwjqwgdg - pnhyqycozc) View more	-	06 Jul 2017
NCT00568334 (CTgov)	Phase 2	Chickenpox	244	Varilrix (inactivated varicella vaccine) (Varilrix HSA-Free Group)	qgjdmqancy(fzblbcroer) = dbqspspezy mpkbwdange (bukjrxvmei, rwcuenymtt - tklcjvnlhr) View more	-	28 Jun 2017
				Varilrix (inactivated varicella vaccine) (Varilrix Group)	qgjdmqancy(fzblbcroer) = hxpknlrjtl mpkbwdange (bukjrxvmei, jricxzhiti - qhapruolyj) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Varicella attenuated live vaccine(Osaka University)

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation